A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas

Completed · Phase 1/Phase 2

Conditions studied: Solid Tumors, Lymphomas

In brief

TSR-011 is a potent small molecule inhibitor of tyrosine kinases involved in cancer, including: 1. Anaplastic lymphoma kinase (ALK) 2. The tropomyosin-related kinases TRKA, TRKB, and TRKC This is a sequential, open-label, non-randomized study with dose escalation in Phase 1, followed by expansion at a recommended phase 2 dose.

Key facts

Study ID

NCT02048488

Run by

Tesaro, Inc.

People needed

72

Starts

2012-10-01

Expected to finish

2018-06-01

Last updated by the study team

2019-03-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• To be considered eligible to participate in this study, all of the following requirements must be met:
• Patients in Phase 1 must have metastatic or locally advanced solid tumors who have failed to respond to standard therapy
• All patients must have confirmation of either ALK positive or TRK positive status.
• Patients in Phase 1 will not be required to have measurable disease. All patients in Phase 2a will be required to have measurable disease by RECIST.
• All patients enrolled in this study must have tumor tissue available.
• Patient (male or female) must be ≥ 18 years of age (except where age of majority is 16 years in a particular country, such as the United Kingdom).
• Patient must have performance status ≤2 on the ECOG Performance Scale.
• Patient must have an estimated life expectancy of at least 3 months.
• Patients must have adequate organ function.
• For patients previously treated with myelosuppressive therapy, at least 3 weeks must have elapsed and toxicity must have recovered to grade 1 or baseline. Non-myelosuppressive therapy patients must have recovered from all treatment-related toxicities. Fourteen days must have elapsed since palliative radiation for bone metastasis.
• Female patients of childbearing potential must have a negative serum pregnancy test and use adequate birth control for the duration of study participation and for 3 months after the last dose of study drug.
• The patient or his or her legal representative must be able to read, understand, and provide signed informed consent.
• Patient is able to understand the study procedures and agrees to participate in the study by giving written informed consent.

You may not qualify if…

• Patients will not be deemed eligible for entry into this study if any of the following criteria are met:
• Patient has leukemia.
• Patient is a pregnant or lactating female.
• Patient has uncontrolled congestive heart failure, angina, or has had a myocardial infarction in the preceding 3 months.
• Ongoing cardiac dysrhythmias of NCI CTCAE Grade ≥2, atrial fibrillation of any grade, or QTc interval >450 msec.
• Patients with risk factors for Torsade de point and patients receiving concomitant medication with QT-prolonging medicines.
• Patient has an uncontrolled concurrent medical condition or disease.
• Patient has undergone bone marrow or stem cell transplantation in the past 6 months.
• Patient has a known hypersensitivity to the components of TSR-011 or the excipients.
• Patient has active or uncontrolled infection.
• Patient has a known psychiatric or substance abuse disorder.
• Patient has active second primary malignancy.
• Patient is observed to have a clinically active central nervous system (CNS) metastases or carcinomatous meningitis.
• Patient has any other severe concurrent disease which, in the judgment of the Investigator, would preclude study participation.
• Patient is known to be HIV positive or who has an AIDS-related illness.
• Patient has a known history of or active (treated or not) Hepatitis B or C.
• Patient has presence of ascites causing significant symptoms.
• A patient must stop taking any prescription, over-the-counter, or herbal remedy known to be an inhibitor or inducer of CYP3A4/5.

Where it is running

• Study site — Goodyear, Arizona, United States
• Study site — Scottsdale, Arizona, United States
• Study site — Los Angeles, California, United States
• Study site — Nashville, Tennessee, United States
• Study site — Norfolk, Virginia, United States
• Study site — Spokane, Washington, United States
• Study site — Poznan, Greater Poland Voivodeship, Poland
• Study site — Warsaw, Masovian Voivodeship, Poland
• Study site — Gdansk, Pomeranian Voivodeship, Poland
• Study site — Olsztyn, Warmian-Masurian Voivodeship, Poland
• Study site — Madrid, Spain
• Study site — Santiago de Compostela, Spain
• Study site — Tainan, Taiwan
• Study site — Taipei, Taiwan
• Study site — London, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.